Opportunity Designed Around Clinical Proof
Initial data from our first-in-human clinical investigations (2025) complement our extensive preclinical studies. Novo-Flex has been used in dental and maxillofacial bone healing cases, demonstrating clear clinical benefits, and earning strong appreciation from surgeons.

Exclusive Technology Licence Agreements
ScaffBon is a spin-out from the University of Bergen (UiB), backed by three signed exclusive license agreements covering patents and know-how developed by the ScaffBon team during their research at UiB on medical devices for orthopedic and dental-maxillofacial applications. ScaffBon holds the exclusive rights to commercialize these game-changing orthopedic technologies.
A Clear Regulatory Pathway for Our MVPs
ScaffBon is pursuing FDA approval through the dental special control 510(k) pathway, which will reduce both costs and time-to-market. This regulatory route was confirmed following a successful Q-Submission to the FDA in March 2026, led by our in-house experts and team. In July 2026, we validated the pathway with FDA reviewers—confirming the predicate device, required testing standards, timeline, and associated costs.
Funded, Validated, and Ready for the Next Step
Our next three years of R&D and FDA clearance work are powered by collaborative projects and grants from the Norwegian Research Council (NFR) and Innovation Norway. In 2026, we secured two competitive industry-related projects—further validating our technology and team.
We are also in dialogue with strategic angel investors who are experts in our domain. We are moving with intent, and this is the stage where most of our investor conversations begin.

Let’s talk about where ScaffBon is headed.
We’re raising a seed round to fund our FDA 510(k). If you invest in early-stage medtech or tissue engineering, we’d like to show you our data.
Write to us to arrange a conversation.
Get in touch